文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

组蛋白去乙酰化酶2（HDAC - 2）在人乳腺癌中的表达的临床意义

Clinical Significance of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer.

作者信息

Garmpis Nikolaos, Damaskos Christos, Dimitroulis Dimitrios, Kouraklis Gregory, Garmpi Anna, Sarantis Panagiotis, Koustas Evangelos, Patsouras Alexandros, Psilopatis Iason, Antoniou Efstathios A, Karamouzis Michail V, Kontzoglou Konstantinos, Nonni Afroditi

机构信息

Second Department of Propedeutic Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.

N.S. Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.

出版信息

J Pers Med. 2022 Oct 8;12(10):1672. doi: 10.3390/jpm12101672.

DOI:10.3390/jpm12101672
PMID:36294811
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9604828/
Abstract

BACKGROUND/AIM: There is a strong association between malignancy and histone deacetylases (HDACs). Histone deacetylase inhibitors (HDACIs) are now being tested as antitumor agents in various clinical trials. We aimed to assess the clinical importance of HDAC-2 in breast cancer (BC). MATERIALS AND METHODS: A total of 118 BC specimens were examined immunohistochemically. A statistical analysis was conducted in order to examine the relation between HDAC-2 and the clinicopathological features and survival of the patients. RESULTS: Higher HDAC-2 expression was related to lobular histological type of cancer, grade III, and stage III BC. In addition, the disease-free period and overall survival were curtailed and negatively related to the over-expression of HDAC-2. Other factors correlating with worse survival were histological types other than ductal or lobular, and the stage of the disease. CONCLUSIONS: This study showed a relationship between HDAC-2 and BC. Further studies are required in order to eventually potentiate the role of HDACIs as anticancer agents in BC.

摘要

背景/目的：恶性肿瘤与组蛋白脱乙酰酶（HDACs）之间存在密切关联。目前，组蛋白脱乙酰酶抑制剂（HDACIs）正在各类临床试验中作为抗肿瘤药物进行测试。我们旨在评估HDAC-2在乳腺癌（BC）中的临床重要性。 材料与方法：对118例乳腺癌标本进行免疫组织化学检查。进行统计分析以检验HDAC-2与患者临床病理特征及生存情况之间的关系。 结果：HDAC-2高表达与小叶组织学类型的癌症、III级和III期乳腺癌相关。此外，无病生存期和总生存期缩短，且与HDAC-2的过表达呈负相关。与较差生存相关的其他因素是除导管或小叶外的组织学类型以及疾病分期。 结论：本研究显示了HDAC-2与乳腺癌之间的关系。为最终增强HDACIs作为乳腺癌抗癌药物的作用，还需要进一步研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc34/9604828/eb4b59acd474/jpm-12-01672-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc34/9604828/3b3516835a5a/jpm-12-01672-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc34/9604828/7c623679e14a/jpm-12-01672-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc34/9604828/60e1a37dd7a1/jpm-12-01672-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc34/9604828/eb4b59acd474/jpm-12-01672-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc34/9604828/3b3516835a5a/jpm-12-01672-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc34/9604828/7c623679e14a/jpm-12-01672-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc34/9604828/60e1a37dd7a1/jpm-12-01672-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc34/9604828/eb4b59acd474/jpm-12-01672-g003.jpg

相似文献

[1]
Clinical Significance of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer.

J Pers Med. 2022-10-8

[2]
Evaluation of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer.

Cancers (Basel). 2024-1-1

[3]
Histone deacetylase (HDAC)-1, -2, -4 and -6 expression in human pancreatic adenocarcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients' survival.

BMC Gastroenterol. 2015-10-26

[4]
Histone Deacetylase (HDAC)-1, -2, -4, and -6 in Uveal Melanomas: Associations with Clinicopathological Parameters and Patients' Survival.

Cancers (Basel). 2021-9-23

[5]
Histone deacetylase-1 and -2 expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival.

J Oral Pathol Med. 2011-4-2

[6]
Small molecule HDAC inhibitors: Promising agents for breast cancer treatment.

Bioorg Chem. 2019-8-5

[7]
Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents.

Curr Med Chem. 2020

[8]
Recent advances in histone deacetylase targeted cancer therapy.

Surg Today. 2010-8-26

[9]
Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas.

BMC Cancer. 2008-8-19

[10]
Clinical Significance of the Immunohistochemical Expression of Histone Deacetylases (HDACs)-2, -4, and -5 in Ovarian Adenocarcinomas.

Biomedicines. 2024-4-24

引用本文的文献

[1]
Cytotoxic Potential and Metabolomic Profiling of Roots Extract and Their Nanocrystals: An Approach.

Integr Cancer Ther. 2025

[2]
Epigenetic modifications in breast cancer: from immune escape mechanisms to therapeutic target discovery.

Front Immunol. 2025-4-17

[3]
Dissecting the epigenetic orchestra of HDAC isoforms in breast cancer development: a review.

Med Oncol. 2024-11-12

[4]
The Epigenetic Modifiers HDAC2 and HDAC7 Inversely Associate with Cancer Stemness and Immunity in Solid Tumors.

Int J Mol Sci. 2024-7-17

[5]
Deciphering the Immune Microenvironment at the Forefront of Tumor Aggressiveness by Constructing a Regulatory Network with Single-Cell and Spatial Transcriptomic Data.

Genes (Basel). 2024-1-15

[6]
Evaluation of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer.

Cancers (Basel). 2024-1-1

[7]
Potential of Dietary HDAC2i in Breast Cancer Patients Receiving PD-1/PD-L1 Inhibitors.

Nutrients. 2023-9-14

[8]
Anti-Colorectal Cancer Activity of Solasonin from L. via Histone Deacetylases-Mediated p53 Acetylation Pathway.

Molecules. 2023-9-15

[9]
Emerging Role of Epigenetic Modifiers in Breast Cancer Pathogenesis and Therapeutic Response.

Cancers (Basel). 2023-8-7

[10]
The Role of Bitter Melon in Breast and Gynecological Cancer Prevention and Therapy.

Int J Mol Sci. 2023-5-17

本文引用的文献

[1]
Role of histone deacetylase inhibitors in diabetic cardiomyopathy in experimental models (Review).

Med Int (Lond). 2022-8-2

[2]
HDAC2- and EZH2-Mediated Histone Modifications Induce PDK1 Expression through miR-148a Downregulation in Breast Cancer Progression and Adriamycin Resistance.

Cancers (Basel). 2022-7-23

[3]
Cancer statistics, 2022.

CA Cancer J Clin. 2022-1

[4]
Histone Deacetylases and their Inhibitors in Colorectal Cancer Therapy: Current Evidence and Future Considerations.

Curr Med Chem. 2022

[5]
Histone deacetylase 2 knockout suppresses immune escape of triple-negative breast cancer cells via downregulating PD-L1 expression.

Cell Death Dis. 2021-8-7

[6]
Investigational Drug Treatments for Triple-Negative Breast Cancer.

J Pers Med. 2021-7-10

[7]
MIER3 induces epithelial-mesenchymal transition and promotes breast cancer cell aggressiveness via forming a co-repressor complex with HDAC1/HDAC2/Snail.

Exp Cell Res. 2021-9-1

[8]
Histone deacetylase‑2: A potential regulator and therapeutic target in liver disease (Review).

Int J Mol Med. 2021-7

[9]
Histone Deacetylase Inhibitors in the Treatment of Hepatocellular Carcinoma: Current Evidence and Future Opportunities.

J Pers Med. 2021-3-22

[10]
MiR-646 prevents proliferation and progression of human breast cancer cell lines by suppressing HDAC2 expression.

Mol Cell Probes. 2020-10

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索